Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7JMX

Crystal structure of a SARS-CoV-2 cross-neutralizing antibody COVA1-16 Fab

Summary for 7JMX
Entry DOI10.2210/pdb7jmx/pdb
DescriptorCOVA1-16 heavy chain, COVA1-16 light chain, SULFATE ION, ... (5 entities in total)
Functional Keywordssars-cov-2, antibody, spike, coronavirus, covid-19, immune system
Biological sourceHomo sapiens
More
Total number of polymer chains2
Total formula weight49691.97
Authors
Liu, H.,Yuan, M.,Zhu, X.,Wu, N.C.,Wilson, I.A. (deposition date: 2020-08-03, release date: 2020-10-14, Last modification date: 2024-10-09)
Primary citationLiu, H.,Wu, N.C.,Yuan, M.,Bangaru, S.,Torres, J.L.,Caniels, T.G.,van Schooten, J.,Zhu, X.,Lee, C.D.,Brouwer, P.J.M.,van Gils, M.J.,Sanders, R.W.,Ward, A.B.,Wilson, I.A.
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Immunity, 53:1272-1280.e5, 2020
Cited by
PubMed Abstract: Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, COVA1-16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here, we determined a crystal structure of the COVA1-16 antibody fragment (Fab) with the SARS-CoV-2 receptor-binding domain (RBD) and negative-stain electron microscopy reconstructions with the spike glycoprotein trimer to elucidate the structural basis of its cross-reactivity. COVA1-16 binds a highly conserved epitope on the SARS-CoV-2 RBD, mainly through a long complementarity-determining region (CDR) H3, and competes with the angiotensin-converting enzyme 2 (ACE2) receptor because of steric hindrance rather than epitope overlap. COVA1-16 binds to a flexible up conformation of the RBD on the spike and relies on antibody avidity for neutralization. These findings, along with the structural and functional rationale for epitope conservation, provide insights for development of more universal SARS-like coronavirus vaccines and therapies.
PubMed: 33242394
DOI: 10.1016/j.immuni.2020.10.023
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.53 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon